VolitionRx is a multinational epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. VolitionRx is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
In this video, Cameron Reynolds, President and CEO of VolitionRx, discusses the company’s Q120 financial results and operating activities. During the quarter, the company made very strong progress in assay and platform development, with its Nu.Q Capture™ programme and epigenetic toolkit, and with its Nu.Q Vet™ collaboration with Texas A&M University. In addition, the company has responded quickly to the COVID-19 pandemic and has a number of clinical trials underway to investigate how its platform might be clinically useful as a diagnostic or prognostic tool for the disease. Financially, VolitionRx has strengthened its balance sheet and ended the quarter with cash and cash equivalents of $12m.